Market capitalization | $637.81m |
Enterprise Value | $331.26m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 1.56 |
P/S ratio (TTM) P/S ratio | 3.00 |
P/B ratio (TTM) P/B ratio | 0.83 |
Revenue growth (TTM) Revenue growth | 11,070.12% |
Revenue (TTM) Revenue | $212.68m |
As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.
13 Analysts have issued a Iovance Biotherapeutics Inc forecast:
13 Analysts have issued a Iovance Biotherapeutics Inc forecast:
Mar '25 |
+/-
%
|
||
Revenue | 213 213 |
11,094%
11,094%
|
|
Gross Profit | 23 23 |
155%
155%
|
|
EBITDA | -354 -354 |
18%
18%
|
EBIT (Operating Income) EBIT | -399 -399 |
15%
15%
|
Net Profit | -375 -375 |
17%
17%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Iovance Biotherapeutics, Inc. operates as a biotechnology company. The firm engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.
Head office | United States |
CEO | Frederick Vogt |
Employees | 838 |
Founded | 2007 |
Website | www.iovance.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.